Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its public reporting. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, and its filings offer insight into the development and commercialization of IMCIVREE (setmelanotide) and related MC4R agonist programs.
Investors can review current reports on Form 8‑K in which Rhythm discusses material events such as quarterly and annual financial results, FDA and EMA regulatory milestones, equity offerings, and amendments to its certificate of incorporation. For example, the company has filed 8‑Ks describing FDA Priority Review and PDUFA goal dates for a supplemental New Drug Application for IMCIVREE in acquired hypothalamic obesity, as well as an 8‑K detailing an underwritten public offering of common stock and intended use of proceeds.
While this page focuses on current reports and other SEC documents, it also serves as a gateway to Rhythm’s periodic reports, where investors typically find detailed information on revenue from global sales of IMCIVREE, research and development expenses, selling, general and administrative expenses, cash position and funding runway. These filings also describe clinical programs in acquired and congenital hypothalamic obesity, genetically caused MC4R pathway diseases and Prader-Willi syndrome, along with investigational agents bivamelagon and RM-718.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as changes in operating expenses, financing transactions, or significant regulatory updates. Real-time ingestion from EDGAR helps surface new Rhythm filings quickly, and users can also monitor items that may relate to executive or director activity when Forms 3, 4 or 5 are filed. This combination of original documents and AI explanations is designed to make RYTM’s complex biopharmaceutical disclosures more accessible to a broad range of investors.
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) filed an 8-K announcing that on July 9, 2025 it entered into an underwriting agreement with Morgan Stanley & Co. LLC and BofA Securities, Inc. to issue 2,058,824 common shares at $85.00 per share. The underwriters fully exercised their 30-day option for an additional 308,823 shares, bringing the total to 2,367,647 shares. Closing is expected on July 11, 2025, subject to customary conditions.
Gross proceeds are about $201.3 million; net proceeds, after underwriting discounts and estimated expenses, are expected to be $188.7 million. The transaction was conducted under the company’s effective Form S-3 shelf registration (File No. 333-270233) and is supported by a legal opinion from Latham & Watkins LLP.
Management plans to deploy the funds to:
- Advance clinical development of pipeline product candidates
- Support commercialization of IMCIVREE
- Provide working capital and cover general corporate purposes
Based on current operating plans, Rhythm believes its existing cash, cash equivalents, short-term investments, and the net proceeds from this offering will fund operations for at least the next 24 months. Forward-looking statements in the filing note that actual cash needs could differ due to market or operational factors.
Key exhibits include the Underwriting Agreement (Ex. 1.1) and related legal opinion (Ex. 5.1).
FAQ
What is the current stock price of Rhythm Pharmaceu (RYTM)?
What is the market cap of Rhythm Pharmaceu (RYTM)?
